Human papillomavirus oncoproteins and apoptosis (Review)

Experimental and Therapeutic Medicine

Volumn 7, Issue 1, 2013, Pages 3-7

  Jiang, Peiyue ^a   Yue, Ying ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Apoptosis; Human papillomavirus; Incorporation; Oncoprotein

Indexed keywords

BH3 PROTEIN; CASPASE; CATHEPSIN B; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOOXYGENASE 2; DEATH RECEPTOR; FAS LIGAND; GLYCOPROTEIN E2; ONCOPROTEIN; PROTEIN BAX; PROTEIN E5; PROTEIN E6; PROTEIN E7; PROTEIN IRE1; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1;

APOPTOSIS; BINDING AFFINITY; CELL TRANSFORMATION; ENDOPLASMIC RETICULUM STRESS; HUMAN; IMMUNE RESPONSE; MITOCHONDRIAL MEMBRANE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; TRANSCRIPTION REGULATION; UBIQUITINATION; WART VIRUS;

EID: 84887930548     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1374     Document Type: Review

References (60)

1. Nichols AC, Palma DA, Chow W, et al: High frequency of activating PIK3CA mutations in human papillomavirus-positive orpharyngeal cancer. JAMA Otolaryngol Head Neck Surg 139: 617-622, 2013.
2. Yuan CH, Filippova M and Duerksen-Hughes P: Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy. Viruses 4: 3831-3850, 2012.
3. Kaspersen MD, Larsen PB, Ingerslev HJ, et al: Identification of multiple HPV types on spermatozoa from human sperm donors. PLoS One 6: e18095, 2011.
4. Schlecht NF, Kulaga S, Robitaille J, et al: Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286: 3106-3114, 2001.
5. Alam MS, Ali A, Mehdi SJ, et al: HPV typing and its relation with apoptosis in cervical carcinoma from Indian population. Tumor Biol 33: 17-22, 2012.
6. Pisani P, Bray F and Parkin DM: Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97: 72-81, 2002.
7. zur Hausen H: Papillomaviruses in the causation of human cancers-a brief historical account. Virology 384: 260-265, 2009.
8. Garnett TO and Duerksen-Hughes PJ: Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. Arch Virol 151: 2321-2335, 2006.
9. Mischo A, Ohlenschläger O, Hortschansky P, Ramachandran R and Görlach M: Structural insights into a wildtype domain of the oncoprotein E6 and its interaction with a PDZ domain. PLoS One8: e62584, 2013.
10. Cai Q, Lv L, Shao Q, Li X and Dian A: Human papillomavirus early proteins and apoptosis. Arch Gynecol Obstet 287: 541-548, 2013.
11. Mantovani F and Banks L: The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene20: 7874-7887, 2001.
12. Nominé Y, Masson M, Charbonnier S, et al: Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol Cell 21: 665-678, 2006.
13. Ristriani T, Nominé Y, Masson M, Weiss E and Travé G: Specific recognition of four-way DNA junctions by the C-terminal zinc-binding domain of HPV oncoprotein E6. J Mol Biol305: 729-739, 2001.
14. Huibregtse JM, Scheffner M and Howley PM: A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus type 16 or 18. EMBO J 10: 4129-4135, 1991.
15. Scheffner M, Huibregtse JM, Vierstra RD and Howley PM: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75: 495-505, 1993.
16. Murray-Zmijewski F, Slee EA and Lu X: A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 9: 702-712, 2008.
17. Howie HL, Katzenellenbogen RA and Galloway DA: Papillomavirus E6 proteins. Virology 384: 324-334, 2009.
18. Blanchette P and Branton PE: Manipulation of the ubiquitin-proteasome pathway by small DNA tumor virus. Virology384: 317-323, 2009.
19. Khoronenkova SV and Dianov GL: The emerging role of Mule and ARF in the regulation of base exicision repair. FEBS Lett585: 2831-2835, 2011.
20. Kumar A, Zhao Y, Meng G, et al: Human papillomovirus oncoperotein E6 inactivates the transcriptional coactivator human ADA3. Mol Cell Biol 22: 5801-5812, 2002.
21. Aylon Y and Oren M: p53: guardian of ploidy. Mol Oncol 5: 315-323, 2011.
22. Contreras-Paredes A, De la Cruz-Hernández E, Martínez-Ramírez I, Dueñas-González A and Lizano M: E6 variants of human papillomavirus 18 differentially modulate the protein kinase B/phosphatidylinositol 3-kinase (akt/PI3K) signaling pathway. Virology 383: 78-85, 2009.
23. Underbrink MP, Howie HL, Bedard KM, Koop JI and GallowayDA: The E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol 82: 10408-10417, 2008.
24. Gewies A: Introduction to apoptosis. Apo Review: 1-26, 2003.
25. Gewin L and Galloway DA: E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-Myc. J Virol 75: 7198-7201, 2001.
26. Venuti A, Paolini F, Nasir L, et al: Papillomavirus E5: the smallest oncoprotein with many functions. Mol Cancer 10: 140, 2011.
27. Chang JL, Tsao YP, Liu DW, Huang SJ, Lee WH and Chen SL: The expression of HPV-16 E5 protein in squamous neoplastic changes in the uterine cervix. J Biomed Sci 8: 206-213, 2001.
28. Conrad M, Bubb VJ and Schlegel R: The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associated with the 16-kilodalton pore-forming protein. J Virol 67: 6170-6178, 1993.
29. Borzacchiello G, Roperto F, Campo MS and Venuti A: 1st international workshop on papillomavirus E5 oncogene-a report. Virology 408: 135-137, 2010.
30. Chen SL and Mounts P: Transforming activity of E5a protein of human papillomavirus type 6 in NIH 3T3 and C127 cells. J Virol64: 3226-3233, 1990.
31. Hu L, Potapova TA, Li S, et al: Expression of HPV16 E5 produces enlarged nuclei and polyploidy through endoreplication. Virology405: 342-351, 2010.
32. Kabsch K and Alonso A: The human papillomavirus type 16 E5 protein impairs TRAIL-and FasL-mediated apoptosis in HaCaT cells by different mechanisms. J Virol 76: 12162-12172, 2002.
33. Wang X, Shi Q, Xu K, et al: Familial CJD associated PrP mutants within transmembrane region induced Ctm-PrP retention in ER and triggered apoptosis by ER stress in SH-SY5Y cells. PLoS One6: e14602, 2011.
34. Xu K, Wang X, Shi Q, et al: Human prion protein mutants with deleted and inserted octarepeats undergo different pathways to trigger cell apoptosis. J Mol Neurosci 43: 225-234, 2011.
35. Sudarshan SR, Schlegel R and Liu XF: The HPV-16 E5 protein represses expression of stress pathway genes XBP-1 and COX-2 in genital keratinocytes. Biochem Biophys Res Commun 399: 617-622, 2010.
36. Condjella R, Liu X, Suprynowicz F, et al: The canine papillomavirus E5 protein signals from the endoplasmic reticulum. J Virol 83: 12833-12841, 2009.
37. Oh JM, Kim SH, Lee YI, et al: Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Carcinogenesis 30: 141-149, 2009.
38. McLaughlin-Drubin ME and Münger K: The human papillomavirus E7 oncoprotein. Virology 384: 335-344, 2009.
39. Toscano-Garibay JD, Benitez-Hess ML and Alvarez-SalasLM: Isolation and characterization of an RNA aptamer of the HPV-16 E7 oncoprotein. Arch Med Res 42: 88-96, 2011.
40. Ohlenschläger O, Seiboth T, Zengerling H, et al: Solution structure of the partially folded high-risk human papillomavirus45 oncoprotein E7. Oncogene 25: 5953-5959, 2006.
41. Liu X, Clements A, Zhao K and Marmorstein R: Structure of human Papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. J Biol Chem281: 578-586, 2006.
42. Ghim S, Jenson AB, Bubier JA, Silva KA, Smith RS and Sundberg JP: Cataracts in transgenic mice caused by a human papillomavirus type 18 E7 oncogene driven by KRT1-14. Exp Mol Pathol 85: 77-82, 2008.
43. Zimmermann M, Koreck A, Meyer N, et al: TNF-like weak inducer of apoptosis (TWEAK) and TNF-alpha cooperate in the induction of keratinocyte apoptosis. J Allergy Clin Immunol 127: 200-207, 2011.
44. Pardali K and Moustakas A: Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775: 21-62, 2007.
45. DeMasi J, Huh KW, Nakatani Y, Münger K and Howley PM: Bovine papillomavirus E7 transformation function correlates with cellular p600 protein binding. Proc Natl Acad Sci USA102: 11486-11491, 2005.
46. DeMasi J, Chao MC, Kumar AS and Howley PM: Bovine papillomavirus E7 oncoprotein inhibits anoikis. J Virol 81: 9419-9425, 2007.
47. Severino A, Abbruzzese C, Manente L, et al: Human papillomavirus-16 E7 interacts with Siva-1 and modulates apoptosis in HaCaT human immortalized keratinocytes. J Cell Physiol 212: 118-125, 2007.
48. Wells SI, Francis DA, Karpova AY, Dowhanick JJ, Benson JD and Howley PM: Papillomavirus E2 induces senescence in HPV-positive cells via pRB-and p21(CIP)-dependent pathway. EMBO J 19: 5762-5771, 2000.
49. Mazumder Indra D, Singh RK, Mitra S, Dutta S, et al: Genetic and epigenetic changes of HPV16 in cervical cancer differentially regulate E6/E7 expression and associate with disease progression. Gynecol Oncol 123: 597-604, 2011.
50. Tang S, Tao M, McCoy JP Jr and Zheng ZM: The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16-or type 18-positive cervical cancer cell lines via translation reinitiation. J Virol 80: 4249-4263, 2006.
51. Dell G and Gaston K: Human papillomavirus and their role in cervical. Cell Mol Life Sci 58: 1923-1942, 2001.
52. Webster K, Parish J, Pandya M, Stern PL, Clarke AR and GastonK: The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem 275: 87-94, 2000.
53. Wu X and Levine AJ: p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci USA 91: 3602-3606, 1994.
54. Frattini MG, Hurst SD, Lim HB, Swaminathan S and LaiminsLA: Abrogation of a mitotic checkpoint by E2 proteins from oncogenic human papillomaviruses correlates with increased turnover of the p53 tumor suppressor protein. EMBO J 16: 318-331, 1997.
55. Bouvard V, Storey A, Pim D and Banks L: Characterization of the human papillomavirus E2 protein: evidence of trans-activation and trans-repression in cervical keratinocytes. EMBO J13: 5451-5459, 1994.
56. Kim K, Gamer-Hamrick PA, Fisher C, Lee D and LambertPF: Methylation patterns of papillomavirus DNA, its influence on E2 function, and implications in viral infection. J Virol 77: 12450-12459, 2003.
57. Dong XP, Stubenrauch F, Beyer-Finkler E and Pfister H: Prevalence of deletions of YY1-binding sites in episomal HPV16 DNA from cervical cancers. Int J Cancer 58: 803-808, 1994.
58. Pett M and Coleman N: Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 212: 356-367, 2007.
59. Arisa-Pulido H, Peyton CL, Joste NE, Vargas H and WheelerCM: Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol44: 1755-1762, 2006.
60. Bhattacharjee B and Sengupta S: CpG methylation of HPV16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2. Virology354: 280-285, 2006.